We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Quintiles and Kaiser Permanente Announce Alliance to Accelerate Drug Development
News

Quintiles and Kaiser Permanente Announce Alliance to Accelerate Drug Development

Quintiles and Kaiser Permanente Announce Alliance to Accelerate Drug Development
News

Quintiles and Kaiser Permanente Announce Alliance to Accelerate Drug Development

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Quintiles and Kaiser Permanente Announce Alliance to Accelerate Drug Development"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Quintiles, the company offering clinical, commercial, consulting and capital solutions worldwide, and Kaiser Permanente’s Southern California Permanente Medical Group (SCPMG) have announced an agreement to help accelerate the development of new and more effective medicines.

The Southern California Permanente Clinical Trials program works on the premise that all clinical trials research should focus on advancing the practice of medical care to improve health outcomes through rigorously designed and executed trials.

Southern California Permanente Medical Group will join Quintiles’ three other prime sites globally, selected for their long-term commitment to clinical research. Clinical research professionals from both Quintiles and SCPMG will work together closely to enhance the productivity and quality of clinical research offered at the SCPMG site. =

Biopharmaceutical companies sponsoring trials will benefit from greater collaboration between clinicians and research professionals, and robust processes for reducing complexity and accelerating trials.

Adam Chasse, Head of Global Prime Sites at Quintiles explains, “Quintiles undertakes more clinical research than any other organization, and that is why our customers rely on us to help them navigate risk and seize opportunity in this new landscape we call the new health. It is therefore critical that we develop alliances with healthcare providers that share our focus on developing new and better medicines while keeping patient care at the forefront. Kaiser Permanente’s rich background in clinical, epidemiologic, and translational research is a natural fit with Quintiles’ core capabilities.”

Donald S. Fong, MD, MPH, Director of Clinical Trials, SCPMG Department of Research & Evaluation, Kaiser Permanente Southern California says, “The Southern California Permanente Clinical Trials program works on the premise that all clinical trials research should focus on advancing the practice of medical care to improve health outcomes through rigorously designed and executed trials.

“Southern California Permanente Clinical Trial investigators are practicing physicians who use their clinical acumen and methodological training to bridge the gap between basic research and clinical practice. Typically, clinical trials research in Kaiser Permanente is aimed at evaluating the impact of interventions at the bedside. This perspective ensures that trials address meaningful questions.”

Quintiles other prime sites are at the University of Pretoria in South Africa, Queen Mary’s College in London, UK and the Washington Hospital Center in Washington DC, USA.
Advertisement